Saltar al contenido
Portada » Ambroxol pediatrico para que sirve

Ambroxol pediatrico para que sirve

  • por
Ambroxol pediatrico para que sirve

Ambroxol syrup for children dosage

There have been reports of serious skin reactions associated with administration of ambroxol. If you develop a skin rash (including mucosal lesions of, for example, the mouth, throat, nose, eyes and genitals), stop using Ambroxol cinfa and consult your doctor immediately.

If you are pregnant or breast-feeding, think you may be pregnant or intend to become pregnant, consult your pharmacist before using this medicine. Treatment with ambroxol has not been shown to be harmful during pregnancy. However, your pharmacist will assess the benefit/risk of its administration.

If you have taken too much Ambroxol cinfa, consult your pharmacist immediately. Take this leaflet with you. No symptoms of overdosage have been reported to date. Treatment in this case will be symptomatic.

Ambroxol cinfa 15 mg/5 ml is supplied in topaz-coloured glass bottles fitted with a white aluminium cap or cylindrical capsule varnished on the inside with a low-density polyethylene foam closure or in topaz PET bottles fitted with a polypropylene cap.

Ambroxol 30 mg for what it is used

Oral route:Intravenous route:Other guideline:1.25-1.6 mg/kg/day orally, intravenously, intramuscularly or subcutaneously, divided into 2-3 doses. Intramuscular and subcutaneous administration is outside the specifications of the data sheet (E: off-label).Patients with renal and hepatic insufficiency:In patients with impaired renal function or severe liver disease, the drug should be administered only under medical supervision and the dose may be reduced or the administration intervals may be increased. Because the drug is metabolized in the liver and eliminated by the kidneys, accumulation of hepatic metabolites of ambroxol is to be expected in case of severe renal insufficiency.Administration:

Ambroxol for cough

Oral route:Intravenous route:Other guideline:1.25-1.6 mg/kg/day orally, intravenously, intramuscularly or subcutaneously, distributed in 2-3 doses. Intramuscular and subcutaneous administration is outside the specifications of the data sheet (E: off-label).Patients with renal and hepatic insufficiency:In patients with impaired renal function or severe liver disease, the drug should be administered only under medical supervision and the dose may be reduced or the administration intervals may be increased. Because the drug is metabolized in the liver and eliminated by the kidneys, accumulation of hepatic metabolites of ambroxol is to be expected in case of severe renal insufficiency.Administration:

Ambroxol for children

Coadjuvant in the treatment of cough. Antitussive and mucolytic drug with surfactant action and minimal sedative action, which is indicated in respiratory processes with increased bronchial secretions and their adherence, such as acute or chronic bronchitis, pneumonia, bronchopneumonia, upper respiratory tract processes such as sinusitis or sinobronchial syndrome and in general in those processes where it is necessary to reduce the effects of cough and obtain a mucolytic effect.

Hypersensitivity to the components of the formula, history of ulcerative dyspepsia, patients under treatment with MAO inhibitors. It should not be administered concomitantly with tranquilizing drugs.

Esta web utiliza cookies propias para su correcto funcionamiento. Al hacer clic en el botón Aceptar, acepta el uso de estas tecnologías y el procesamiento de tus datos para estos propósitos. Más información
Privacidad